Prediction of Incomplete Response of Primary Tumour Based on Clinical and Radiomics Features in Inoperable Head and Neck Cancers after Definitive Treatment.
head and neck cancer
incomplete response
predictive models
radiomics
radiotherapy
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
30 Jun 2022
30 Jun 2022
Historique:
received:
08
06
2022
revised:
27
06
2022
accepted:
28
06
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Radical treatment of patients diagnosed with inoperable and locally advanced head and neck cancers (LAHNC) is still a challenge for clinicians. Prediction of incomplete response (IR) of primary tumour would be of value to the treatment optimization for patients with LAHNC. Aim of this study was to develop and evaluate models based on clinical and radiomics features for prediction of IR in patients diagnosed with LAHNC and treated with definitive chemoradiation or radiotherapy. Clinical and imaging data of 290 patients were included into this retrospective study. Clinical model was built based on tumour and patient related features. Radiomics features were extracted based on imaging data, consisting of contrast- and non-contrast-enhanced pre-treatment CT images, obtained in process of diagnosis and radiotherapy planning. Performance of clinical and combined models were evaluated with area under the ROC curve (AUROC). Classification performance was evaluated using 5-fold cross validation. Model based on selected clinical features including ECOG performance, tumour stage T3/4, primary site: oral cavity and tumour volume were significantly predictive for IR, with AUROC of 0.78. Combining clinical and radiomics features did not improve model's performance, achieving AUROC 0.77 and 0.68 for non-contrast enhanced and contrast-enhanced images respectively. The model based on clinical features showed good performance in IR prediction. Combined model performance suggests that real-world imaging data might not yet be ready for use in predictive models.
Identifiants
pubmed: 35887587
pii: jpm12071092
doi: 10.3390/jpm12071092
pmc: PMC9317569
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Clin Transl Radiat Oncol. 2017 Aug 04;6:1-6
pubmed: 29594216
Radiother Oncol. 2021 Jan;154:70-75
pubmed: 32861702
Acta Oncol. 2013 Feb;52(2):285-93
pubmed: 23320773
Sci Rep. 2022 Feb 24;12(1):3183
pubmed: 35210482
Sci Rep. 2017 Aug 31;7(1):10117
pubmed: 28860628
Radiother Oncol. 2006 Apr;79(1):15-20
pubmed: 16616387
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
Acta Oncol. 2016 May;55(5):625-32
pubmed: 27045977
Radiother Oncol. 2018 Jan;126(1):3-24
pubmed: 29180076
Nat Commun. 2014 Jun 03;5:4006
pubmed: 24892406
Oral Oncol. 2015 Jul;51(7):709-15
pubmed: 25958830
Cancer Imaging. 2021 May 20;21(1):37
pubmed: 34016188
PLoS One. 2020 May 22;15(5):e0232639
pubmed: 32442178
J Pers Med. 2021 Mar 18;11(3):
pubmed: 33803592
Oral Oncol. 2021 Jan;112:105083
pubmed: 33189001
J Med Imaging Radiat Oncol. 2013 Aug;57(4):503-11
pubmed: 23870352
Oral Oncol. 2018 May;80:16-22
pubmed: 29706184
Radiother Oncol. 2020 May;146:58-65
pubmed: 32114267
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Sci Rep. 2019 Feb 26;9(1):2764
pubmed: 30809047
Front Oncol. 2021 May 27;11:664304
pubmed: 34123824
J Pers Med. 2022 Jan 21;12(2):
pubmed: 35207631
Cancers (Basel). 2021 Sep 11;13(18):
pubmed: 34572786